Review



rnf8 guide rna  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology rnf8 guide rna
    Fig. 1. Expression of <t>RNF8</t> is increased in cisplatin and doxorubicin resistant EC cells. A Cell viability of ISH-WT, ISH-Cis-R, B AN3CA-WT and AN3CA-Cis-R cells. Cisplatin con- centrations are 0 mM, 5 mM, 10 mM, 20 mM, and 40 mM. Data are represented as mean ± standard deviations (SD) of three independent experiments. C Cell viability of ISH-WT, ISH- Dox-R, D AN3CA-WT and AN3CA-Dox-R cells. Doxorubicin concentrations are 0 mM, 1 mM, 2 mM, 4 mM, and 8 mM. Data are represented as mean ± SD of three independent ex- periments. E RNF8 mRNA expression in ISH-WT, ISH-Cis-R, F AN3CA-WT, AN3CA-Cis-R, G ISH-WT, ISH-Dox-R, H AN3CA-WT and AN3CA-Dox-R cells. ***: P < 0.001. I Western blotting analysis of RNF8 protein expression in ISH-WT, ISH-Cis-R, AN3CA-WT and AN3CA-Cis-R, ISH-WT, ISH-Dox-R, AN3CA-WT and AN3CA-Dox-R cells. J RNF8 mRNA expression in EC patient samples. Platinum sensitive group: n ¼ 32. Platinum resistant group: n ¼ 32. ***: p < 0.001.
    Rnf8 Guide Rna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rnf8+guide+rna/RNF8+CRISPR%2FCas9+KO+Plasmid/pm33548629-65-10-16
    Average 92 stars, based on 2 article reviews
    rnf8 guide rna - by Bioz Stars, 2026-09
    92/100 stars

    Images

    1) Product Images from "Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer."

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.

    Journal: Biochemical and biophysical research communications

    doi: 10.1016/j.bbrc.2021.01.046

    Fig. 1. Expression of RNF8 is increased in cisplatin and doxorubicin resistant EC cells. A Cell viability of ISH-WT, ISH-Cis-R, B AN3CA-WT and AN3CA-Cis-R cells. Cisplatin con- centrations are 0 mM, 5 mM, 10 mM, 20 mM, and 40 mM. Data are represented as mean ± standard deviations (SD) of three independent experiments. C Cell viability of ISH-WT, ISH- Dox-R, D AN3CA-WT and AN3CA-Dox-R cells. Doxorubicin concentrations are 0 mM, 1 mM, 2 mM, 4 mM, and 8 mM. Data are represented as mean ± SD of three independent ex- periments. E RNF8 mRNA expression in ISH-WT, ISH-Cis-R, F AN3CA-WT, AN3CA-Cis-R, G ISH-WT, ISH-Dox-R, H AN3CA-WT and AN3CA-Dox-R cells. ***: P < 0.001. I Western blotting analysis of RNF8 protein expression in ISH-WT, ISH-Cis-R, AN3CA-WT and AN3CA-Cis-R, ISH-WT, ISH-Dox-R, AN3CA-WT and AN3CA-Dox-R cells. J RNF8 mRNA expression in EC patient samples. Platinum sensitive group: n ¼ 32. Platinum resistant group: n ¼ 32. ***: p < 0.001.
    Figure Legend Snippet: Fig. 1. Expression of RNF8 is increased in cisplatin and doxorubicin resistant EC cells. A Cell viability of ISH-WT, ISH-Cis-R, B AN3CA-WT and AN3CA-Cis-R cells. Cisplatin con- centrations are 0 mM, 5 mM, 10 mM, 20 mM, and 40 mM. Data are represented as mean ± standard deviations (SD) of three independent experiments. C Cell viability of ISH-WT, ISH- Dox-R, D AN3CA-WT and AN3CA-Dox-R cells. Doxorubicin concentrations are 0 mM, 1 mM, 2 mM, 4 mM, and 8 mM. Data are represented as mean ± SD of three independent ex- periments. E RNF8 mRNA expression in ISH-WT, ISH-Cis-R, F AN3CA-WT, AN3CA-Cis-R, G ISH-WT, ISH-Dox-R, H AN3CA-WT and AN3CA-Dox-R cells. ***: P < 0.001. I Western blotting analysis of RNF8 protein expression in ISH-WT, ISH-Cis-R, AN3CA-WT and AN3CA-Cis-R, ISH-WT, ISH-Dox-R, AN3CA-WT and AN3CA-Dox-R cells. J RNF8 mRNA expression in EC patient samples. Platinum sensitive group: n ¼ 32. Platinum resistant group: n ¼ 32. ***: p < 0.001.

    Techniques Used: Expressing, Western Blot

    Fig. 2. Depletion of RNF8 sensitize cisplatin and doxorubicin resistant EC cells. A Western blotting analysis of RNF8 protein expression in AN3CA-Cis-R-Ctr, RNF8 knockout AN3CA- Cis-R clone 1 (AN3CA-Cis-R-KO1), RNF8 knockout AN3CA-Cis-R clone 2 (AN3CA-Cis-R-KO2), RNF8 ectopic expressed AN3CA-Cis-R-KO1 (AN3CA-Cis-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Cis-R-KO2 (AN3CA-Cis-R-KO2þRNF8), B AN3CA-Dox-R-Ctr, RNF8 knockout AN3CA-Dox-R clone 1 (AN3CA-Dox-R-KO1), RNF8 knockout AN3CA-Dox-R clone 2 (AN3CA-Dox-R-KO2), RNF8 ectopic expressed AN3CA-Dox-R-KO1 (AN3CA-Dox-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Dox-R-KO2 (AN3CA-Dox-R-KO2þRNF8) cells. C Cell viability of AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA-Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells to cisplatin. Data are represented as mean ± SD of three independent experiments. D Cell viability of AN3CA-Dox-R-Ctr, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells to doxo- rubicin. Data are represented as mean ± SD of three independent experiments.
    Figure Legend Snippet: Fig. 2. Depletion of RNF8 sensitize cisplatin and doxorubicin resistant EC cells. A Western blotting analysis of RNF8 protein expression in AN3CA-Cis-R-Ctr, RNF8 knockout AN3CA- Cis-R clone 1 (AN3CA-Cis-R-KO1), RNF8 knockout AN3CA-Cis-R clone 2 (AN3CA-Cis-R-KO2), RNF8 ectopic expressed AN3CA-Cis-R-KO1 (AN3CA-Cis-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Cis-R-KO2 (AN3CA-Cis-R-KO2þRNF8), B AN3CA-Dox-R-Ctr, RNF8 knockout AN3CA-Dox-R clone 1 (AN3CA-Dox-R-KO1), RNF8 knockout AN3CA-Dox-R clone 2 (AN3CA-Dox-R-KO2), RNF8 ectopic expressed AN3CA-Dox-R-KO1 (AN3CA-Dox-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Dox-R-KO2 (AN3CA-Dox-R-KO2þRNF8) cells. C Cell viability of AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA-Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells to cisplatin. Data are represented as mean ± SD of three independent experiments. D Cell viability of AN3CA-Dox-R-Ctr, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells to doxo- rubicin. Data are represented as mean ± SD of three independent experiments.

    Techniques Used: Western Blot, Expressing, Knock-Out

    Fig. 3. RNF8 deficiency reduces NHEJ efficiency in cisplatin and doxorubicin resistant EC cells. A Relative NHEJ events in AN3CA-Cis-R, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA- Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. **: P < 0.01. B Relative NHEJ events in AN3CA-Dox-R, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. ***: P < 0.001. C Localization of Ku80 at DNA damage sites upon DNA damage in AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1 and AN3CA-Cis-R-KO1þRNF8 cells. Cells were subjected to
    Figure Legend Snippet: Fig. 3. RNF8 deficiency reduces NHEJ efficiency in cisplatin and doxorubicin resistant EC cells. A Relative NHEJ events in AN3CA-Cis-R, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA- Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. **: P < 0.01. B Relative NHEJ events in AN3CA-Dox-R, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. ***: P < 0.001. C Localization of Ku80 at DNA damage sites upon DNA damage in AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1 and AN3CA-Cis-R-KO1þRNF8 cells. Cells were subjected to

    Techniques Used:

    Fig. 4. Inhibition of RNF8 increases sensitivity to cisplatin in vivo. A Photograph of tumors dissected from mice at day 21 in AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft. Female BALB/c nude mice were treated intraperitoneally with vehicle (DMSO) or cisplatin (8 mg/kg/3 days). Group size: 6 mice/group. B Tumor growth, C Tumor size and D body weight of AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft in response to cisplatin. *: p < 0.05, ****: p < 0.0001.
    Figure Legend Snippet: Fig. 4. Inhibition of RNF8 increases sensitivity to cisplatin in vivo. A Photograph of tumors dissected from mice at day 21 in AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft. Female BALB/c nude mice were treated intraperitoneally with vehicle (DMSO) or cisplatin (8 mg/kg/3 days). Group size: 6 mice/group. B Tumor growth, C Tumor size and D body weight of AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft in response to cisplatin. *: p < 0.05, ****: p < 0.0001.

    Techniques Used: Inhibition, In Vivo

    Related Articles

    CRISPR:

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
    Article Snippet: .. Background: Endometrial cancer (EC) is one of the most frequent gynecological malignancy worldwide.. However, resistance to chemotherapy remains one of the major difficulties in the treatment of EC.. Thus, there is an urgent requirement to understand mechanisms of chemoresistance and identify novel regimens for patients with EC. ..

    Plasmid Preparation:

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
    Article Snippet: .. Background: Endometrial cancer (EC) is one of the most frequent gynecological malignancy worldwide.. However, resistance to chemotherapy remains one of the major difficulties in the treatment of EC.. Thus, there is an urgent requirement to understand mechanisms of chemoresistance and identify novel regimens for patients with EC. ..

    Transfection:

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
    Article Snippet: .. Background: Endometrial cancer (EC) is one of the most frequent gynecological malignancy worldwide.. However, resistance to chemotherapy remains one of the major difficulties in the treatment of EC.. Thus, there is an urgent requirement to understand mechanisms of chemoresistance and identify novel regimens for patients with EC. ..

    other:

    Article Title: Targeting RNF8 Effectively Reverse Cisplatin and Doxorubicin Resistance in Endometrial Cancer
    Article Snippet: Subsequently the Fast SYBR Green Master Mix (ThermoFisher Scienti c) was used for qPCR to detect the mRNA levels of RNF8, according to the manufacturer’s instructions using a Real-Time PCR system (Eppendorf Thermal Cycler Eco; Eppendorf).



    Similar Products

    rnf8 guide rna  (Santa Cruz Biotechnology)
    92
    Santa Cruz Biotechnology rnf8 guide rna
    Fig. 1. Expression of <t>RNF8</t> is increased in cisplatin and doxorubicin resistant EC cells. A Cell viability of ISH-WT, ISH-Cis-R, B AN3CA-WT and AN3CA-Cis-R cells. Cisplatin con- centrations are 0 mM, 5 mM, 10 mM, 20 mM, and 40 mM. Data are represented as mean ± standard deviations (SD) of three independent experiments. C Cell viability of ISH-WT, ISH- Dox-R, D AN3CA-WT and AN3CA-Dox-R cells. Doxorubicin concentrations are 0 mM, 1 mM, 2 mM, 4 mM, and 8 mM. Data are represented as mean ± SD of three independent ex- periments. E RNF8 mRNA expression in ISH-WT, ISH-Cis-R, F AN3CA-WT, AN3CA-Cis-R, G ISH-WT, ISH-Dox-R, H AN3CA-WT and AN3CA-Dox-R cells. ***: P < 0.001. I Western blotting analysis of RNF8 protein expression in ISH-WT, ISH-Cis-R, AN3CA-WT and AN3CA-Cis-R, ISH-WT, ISH-Dox-R, AN3CA-WT and AN3CA-Dox-R cells. J RNF8 mRNA expression in EC patient samples. Platinum sensitive group: n ¼ 32. Platinum resistant group: n ¼ 32. ***: p < 0.001.
    Rnf8 Guide Rna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rnf8+guide+rna/RNF8+CRISPR%2FCas9+KO+Plasmid/pm33548629-65-10-16
    Average 92 stars, based on 1 article reviews
    rnf8 guide rna - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1. Expression of RNF8 is increased in cisplatin and doxorubicin resistant EC cells. A Cell viability of ISH-WT, ISH-Cis-R, B AN3CA-WT and AN3CA-Cis-R cells. Cisplatin con- centrations are 0 mM, 5 mM, 10 mM, 20 mM, and 40 mM. Data are represented as mean ± standard deviations (SD) of three independent experiments. C Cell viability of ISH-WT, ISH- Dox-R, D AN3CA-WT and AN3CA-Dox-R cells. Doxorubicin concentrations are 0 mM, 1 mM, 2 mM, 4 mM, and 8 mM. Data are represented as mean ± SD of three independent ex- periments. E RNF8 mRNA expression in ISH-WT, ISH-Cis-R, F AN3CA-WT, AN3CA-Cis-R, G ISH-WT, ISH-Dox-R, H AN3CA-WT and AN3CA-Dox-R cells. ***: P < 0.001. I Western blotting analysis of RNF8 protein expression in ISH-WT, ISH-Cis-R, AN3CA-WT and AN3CA-Cis-R, ISH-WT, ISH-Dox-R, AN3CA-WT and AN3CA-Dox-R cells. J RNF8 mRNA expression in EC patient samples. Platinum sensitive group: n ¼ 32. Platinum resistant group: n ¼ 32. ***: p < 0.001.

    Journal: Biochemical and biophysical research communications

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.

    doi: 10.1016/j.bbrc.2021.01.046

    Figure Lengend Snippet: Fig. 1. Expression of RNF8 is increased in cisplatin and doxorubicin resistant EC cells. A Cell viability of ISH-WT, ISH-Cis-R, B AN3CA-WT and AN3CA-Cis-R cells. Cisplatin con- centrations are 0 mM, 5 mM, 10 mM, 20 mM, and 40 mM. Data are represented as mean ± standard deviations (SD) of three independent experiments. C Cell viability of ISH-WT, ISH- Dox-R, D AN3CA-WT and AN3CA-Dox-R cells. Doxorubicin concentrations are 0 mM, 1 mM, 2 mM, 4 mM, and 8 mM. Data are represented as mean ± SD of three independent ex- periments. E RNF8 mRNA expression in ISH-WT, ISH-Cis-R, F AN3CA-WT, AN3CA-Cis-R, G ISH-WT, ISH-Dox-R, H AN3CA-WT and AN3CA-Dox-R cells. ***: P < 0.001. I Western blotting analysis of RNF8 protein expression in ISH-WT, ISH-Cis-R, AN3CA-WT and AN3CA-Cis-R, ISH-WT, ISH-Dox-R, AN3CA-WT and AN3CA-Dox-R cells. J RNF8 mRNA expression in EC patient samples. Platinum sensitive group: n ¼ 32. Platinum resistant group: n ¼ 32. ***: p < 0.001.

    Article Snippet: A pool of 3 plasmids encoding Cas9 coding gene and RNF8 guide RNA (cat. no. sc-401909; Santa Crus Biotechnology, Inc.) or CRISPR/ Cas9-Ctr Plasmid (cat. no. sc-418922; Santa Crus Biotechnology, Inc.) was transfected into AN3CA Cis-R and AN3CA Dox-R cells using Lipofectamine® 2000.

    Techniques: Expressing, Western Blot

    Fig. 2. Depletion of RNF8 sensitize cisplatin and doxorubicin resistant EC cells. A Western blotting analysis of RNF8 protein expression in AN3CA-Cis-R-Ctr, RNF8 knockout AN3CA- Cis-R clone 1 (AN3CA-Cis-R-KO1), RNF8 knockout AN3CA-Cis-R clone 2 (AN3CA-Cis-R-KO2), RNF8 ectopic expressed AN3CA-Cis-R-KO1 (AN3CA-Cis-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Cis-R-KO2 (AN3CA-Cis-R-KO2þRNF8), B AN3CA-Dox-R-Ctr, RNF8 knockout AN3CA-Dox-R clone 1 (AN3CA-Dox-R-KO1), RNF8 knockout AN3CA-Dox-R clone 2 (AN3CA-Dox-R-KO2), RNF8 ectopic expressed AN3CA-Dox-R-KO1 (AN3CA-Dox-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Dox-R-KO2 (AN3CA-Dox-R-KO2þRNF8) cells. C Cell viability of AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA-Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells to cisplatin. Data are represented as mean ± SD of three independent experiments. D Cell viability of AN3CA-Dox-R-Ctr, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells to doxo- rubicin. Data are represented as mean ± SD of three independent experiments.

    Journal: Biochemical and biophysical research communications

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.

    doi: 10.1016/j.bbrc.2021.01.046

    Figure Lengend Snippet: Fig. 2. Depletion of RNF8 sensitize cisplatin and doxorubicin resistant EC cells. A Western blotting analysis of RNF8 protein expression in AN3CA-Cis-R-Ctr, RNF8 knockout AN3CA- Cis-R clone 1 (AN3CA-Cis-R-KO1), RNF8 knockout AN3CA-Cis-R clone 2 (AN3CA-Cis-R-KO2), RNF8 ectopic expressed AN3CA-Cis-R-KO1 (AN3CA-Cis-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Cis-R-KO2 (AN3CA-Cis-R-KO2þRNF8), B AN3CA-Dox-R-Ctr, RNF8 knockout AN3CA-Dox-R clone 1 (AN3CA-Dox-R-KO1), RNF8 knockout AN3CA-Dox-R clone 2 (AN3CA-Dox-R-KO2), RNF8 ectopic expressed AN3CA-Dox-R-KO1 (AN3CA-Dox-R-KO1þRNF8), RNF8 ectopic expressed AN3CA-Dox-R-KO2 (AN3CA-Dox-R-KO2þRNF8) cells. C Cell viability of AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA-Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells to cisplatin. Data are represented as mean ± SD of three independent experiments. D Cell viability of AN3CA-Dox-R-Ctr, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells to doxo- rubicin. Data are represented as mean ± SD of three independent experiments.

    Article Snippet: A pool of 3 plasmids encoding Cas9 coding gene and RNF8 guide RNA (cat. no. sc-401909; Santa Crus Biotechnology, Inc.) or CRISPR/ Cas9-Ctr Plasmid (cat. no. sc-418922; Santa Crus Biotechnology, Inc.) was transfected into AN3CA Cis-R and AN3CA Dox-R cells using Lipofectamine® 2000.

    Techniques: Western Blot, Expressing, Knock-Out

    Fig. 3. RNF8 deficiency reduces NHEJ efficiency in cisplatin and doxorubicin resistant EC cells. A Relative NHEJ events in AN3CA-Cis-R, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA- Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. **: P < 0.01. B Relative NHEJ events in AN3CA-Dox-R, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. ***: P < 0.001. C Localization of Ku80 at DNA damage sites upon DNA damage in AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1 and AN3CA-Cis-R-KO1þRNF8 cells. Cells were subjected to

    Journal: Biochemical and biophysical research communications

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.

    doi: 10.1016/j.bbrc.2021.01.046

    Figure Lengend Snippet: Fig. 3. RNF8 deficiency reduces NHEJ efficiency in cisplatin and doxorubicin resistant EC cells. A Relative NHEJ events in AN3CA-Cis-R, AN3CA-Cis-R-KO1, AN3CA-Cis-R-KO2, AN3CA- Cis-R-KO1þRNF8 and AN3CA-Cis-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. **: P < 0.01. B Relative NHEJ events in AN3CA-Dox-R, AN3CA-Dox-R-KO1, AN3CA-Dox-R-KO2, AN3CA-Dox-R-KO1þRNF8, AN3CA-Dox-R-KO2þRNF8 cells. Data are represented as mean ± SD of three independent experiments. ***: P < 0.001. C Localization of Ku80 at DNA damage sites upon DNA damage in AN3CA-Cis-R-Ctr, AN3CA-Cis-R-KO1 and AN3CA-Cis-R-KO1þRNF8 cells. Cells were subjected to

    Article Snippet: A pool of 3 plasmids encoding Cas9 coding gene and RNF8 guide RNA (cat. no. sc-401909; Santa Crus Biotechnology, Inc.) or CRISPR/ Cas9-Ctr Plasmid (cat. no. sc-418922; Santa Crus Biotechnology, Inc.) was transfected into AN3CA Cis-R and AN3CA Dox-R cells using Lipofectamine® 2000.

    Techniques:

    Fig. 4. Inhibition of RNF8 increases sensitivity to cisplatin in vivo. A Photograph of tumors dissected from mice at day 21 in AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft. Female BALB/c nude mice were treated intraperitoneally with vehicle (DMSO) or cisplatin (8 mg/kg/3 days). Group size: 6 mice/group. B Tumor growth, C Tumor size and D body weight of AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft in response to cisplatin. *: p < 0.05, ****: p < 0.0001.

    Journal: Biochemical and biophysical research communications

    Article Title: Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.

    doi: 10.1016/j.bbrc.2021.01.046

    Figure Lengend Snippet: Fig. 4. Inhibition of RNF8 increases sensitivity to cisplatin in vivo. A Photograph of tumors dissected from mice at day 21 in AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft. Female BALB/c nude mice were treated intraperitoneally with vehicle (DMSO) or cisplatin (8 mg/kg/3 days). Group size: 6 mice/group. B Tumor growth, C Tumor size and D body weight of AN3CA-Cis-R-Ctr and AN3CA-Cis-R-KO1 xenograft in response to cisplatin. *: p < 0.05, ****: p < 0.0001.

    Article Snippet: A pool of 3 plasmids encoding Cas9 coding gene and RNF8 guide RNA (cat. no. sc-401909; Santa Crus Biotechnology, Inc.) or CRISPR/ Cas9-Ctr Plasmid (cat. no. sc-418922; Santa Crus Biotechnology, Inc.) was transfected into AN3CA Cis-R and AN3CA Dox-R cells using Lipofectamine® 2000.

    Techniques: Inhibition, In Vivo